We are live on ! Find out more
ISEE

IVERIC bio, Inc. Common Stock

Delisted

ISEE was delisted on the 10th of July, 2023.

184 hedge funds and large institutions have $1.11B invested in IVERIC bio, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 61 increasing their positions, 54 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

128% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 18

118% more call options, than puts

Call options by funds: $33M | Put options by funds: $15.1M

13% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 54

13% more funds holding

Funds holding: 163184 (+21)

42% less funds holding in top 10

Funds holding in top 10: 127 (-5)

44% less capital invested

Capital invested by funds: $1.99B → $1.11B (-$874M)

Holders
184
Holders Change
+21
Holders Change %
+12.88%
% of All Funds
3.1%
Holding in Top 10
7
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-41.67%
% of All Funds
0.12%
New
41
Increased
61
Reduced
54
Closed
18
Calls
$33M
Puts
$15.1M
Net Calls
+$17.9M
Net Calls Change
-$18.1M
Name Holding Trade Value Shares
Change
Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$10.4M +$376K +29,926 +3%
5VM
27
5AM Venture Management
California
$9.89M
N
28
Nuveen
North Carolina
$9.87M +$2.99M +237,825 +30%
SB
29
Samsara BioCapital
California
$9.72M -$3.17M -252,500 -20%
FC
30
Finepoint Capital
Massachusetts
$9.5M +$12.4M +987,600 New
SFM
31
Sphera Funds Management
Israel
$9.26M +$2.36M +188,340 +24%
JP Morgan Chase
32
JP Morgan Chase
New York
$8.88M +$4.79M +381,732 +70%
SCM
33
Soleus Capital Management
Connecticut
$8.8M -$629K -50,130 -5%
PHS
34
PFM Health Sciences
California
$8.72M -$1.25M -99,200 -10%
Morgan Stanley
35
Morgan Stanley
New York
$8.27M -$24M -1,908,551 -69%
Goldman Sachs
36
Goldman Sachs
New York
$7.34M +$4.29M +342,115 +81%
PVI
37
Pura Vida Investments
New York
$6.88M -$1.88M -150,000 -17%
LPC
38
Lion Point Capital
New York
$6.61M
SI
39
Sofinnova Investments
California
$6.28M -$4.62M -368,164 -36%
ABG
40
Ally Bridge Group
New York
$6.25M
Walleye Capital
41
Walleye Capital
New York
$5.9M +$1.02M +81,020 +15%
ACP
42
Acuta Capital Partners
California
$5.42M +$303K +24,107 +4%
Balyasny Asset Management
43
Balyasny Asset Management
Illinois
$4.84M +$6.31M +502,893 New
GTC
44
Ghost Tree Capital
New York
$4.81M +$628K +50,000 +11%
Fidelity Investments
45
Fidelity Investments
Massachusetts
$4.45M +$5.44M +433,512 +1,486%
Ensign Peak Advisors
46
Ensign Peak Advisors
Utah
$4.24M +$2.92M +232,806 +112%
APM
47
Avidity Partners Management
Texas
$4.14M -$75.9M -6,045,283 -93%
DCM
48
DAFNA Capital Management
California
$3.87M +$1.31M +104,000 +35%
Bank of New York Mellon
49
Bank of New York Mellon
New York
$3.7M -$1.28M -102,044 -21%
Citigroup
50
Citigroup
New York
$3.48M +$3.74M +297,620 +467%

ISEE Hedge Fund Activity: Q2 2022 in Review

184 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q2 2022, worth a combined $1.11B — down 44% from $1.99B a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new ISEE positions and 18 closed out — a net gain of 23 holders — while 61 added to existing stakes and 54 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $84.2M. The largest seller was Avidity Partners Management, cutting an estimated $75.9M.

  • 184 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q2 2022, up from 163 in Q1 2022.
  • Funds reported $1.11B of IVERIC bio, Inc. Common Stock stock for Q2 2022, down 44% quarter-over-quarter.
  • 41 funds opened new IVERIC bio, Inc. Common Stock positions in Q2 2022 and 18 closed out, a net change of +23 holders.
  • The largest IVERIC bio, Inc. Common Stock buyer in Q2 2022 was Janus Henderson Group, an estimated $84.2M added.
  • The largest IVERIC bio, Inc. Common Stock seller in Q2 2022 was Avidity Partners Management, an estimated $75.9M sold.

Based on aggregated 13F filings for Q2 2022.